![A trial comparing lapatinib and capecitabine with trastuzumab and capecitabine for breast cancer that has spread (CEREBEL) | Cancer Research UK A trial comparing lapatinib and capecitabine with trastuzumab and capecitabine for breast cancer that has spread (CEREBEL) | Cancer Research UK](https://www.cancerresearchuk.org/sites/default/files/styles/cruk_wide_resp_breakpoint_one/public/5641-bar-chart-2.png?itok=Oxh60oU9)
A trial comparing lapatinib and capecitabine with trastuzumab and capecitabine for breast cancer that has spread (CEREBEL) | Cancer Research UK
![Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®) - ScienceDirect Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1462388904000535-gr5.jpg)
Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®) - ScienceDirect
![Cureus | Hyperpigmentation with Capecitabine: Part of Hand-Foot Syndrome or a Separate Entity? | Article Cureus | Hyperpigmentation with Capecitabine: Part of Hand-Foot Syndrome or a Separate Entity? | Article](https://assets.cureus.com/uploads/figure/file/32276/article_river_571cc1602cc211e8b9426fdb8651bcaa-picture-1.v1.png)
Cureus | Hyperpigmentation with Capecitabine: Part of Hand-Foot Syndrome or a Separate Entity? | Article
![Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuously Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuously](https://www.spandidos-publications.com/article_images/ol/3/6/OL-03-06-1191-g00.jpg)